Skip to main content
Contact Us
Subscribe
E-Edition
39°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
(OP:
NUMIF
)
0.0302
-0.0188 (-38.37%)
Streaming Delayed Price
Updated: 3:13 PM EST, Feb 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about NUMIF
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Psychedelics Company Numinus Wellness Consolidates Recent Surge Higher: What's Going On?
January 18, 2023
Numinus Wellness, Inc (OTC: NUMIF) was consolidating about 2% lower on Wednesday after surging over 30% on Tuesday.
Via
Benzinga
Psychedelics Company Numinus Wellness Reports Q1 2023 Earnings, Initiatives For Wider Access
January 18, 2023
Mental healthcare psychedelics company Numinus Wellness (OTCQX: NUMIF) shared its financial results for the three months ended November 30, 2022.
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 17, 2023
January 17, 2023
Via
Benzinga
Numinus Wellness Inc. Reports Q1 2023 Results
January 17, 2023
Q1 2023 revenues grew 618% year-over-year to $5.7 million Q1 2023 gross margin grew to 41.9% from 31.5% in prior quarter Gross profit of $2.4 million, an increase of $1.1 million from prior quarter...
Via
PressReach
GH Research, Cybin Among Top Psychedelic Movers Of Today
January 16, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 11, 2023
January 11, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 10, 2023
January 10, 2023
Via
Benzinga
ATAI Life Sciences, Cybin Among Top Psychedelic Movers Of Today
January 06, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 13, 2023
January 13, 2023
Via
Benzinga
Intelgenx Technologies, Cybin Among Top Psychedelic Movers Of Today
January 12, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 9, 2023
January 09, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 5, 2023
January 05, 2023
Via
Benzinga
Seelos Therapeutics, Cybin Among Top Psychedelic Movers Of Today
January 04, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 3, 2023
January 03, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From December 9, 2022
December 09, 2022
Via
Benzinga
Psychedelic Stock Gainers And Losers From December 7, 2022
December 07, 2022
Via
Benzinga
Largest Psychedelic Stocks DOWN 8% Last Week; DOWN 22% So Far This Month
December 25, 2022
Today's article highlights the performance of the munKNEE Psychedelic Drug Stocks Index which tracks the six (6) largest psychedelic stocks researching the treatment of mental illnesses based on the...
Via
Talk Markets
Seelos Therapeutics, Mind Medicine Among Top Psychedelic Movers Of Today
December 16, 2022
Via
Benzinga
KCSA Mental Health Virtual Investor Conference: Presentations Now Available for Online Viewing
December 16, 2022
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Seelos Therapeutics, Cybin Among Top Psychedelic Movers Of Today
December 15, 2022
Via
Benzinga
Psyched: Psychedelic Therapy In The Workplace, UCL's Brain Imaging Study, COMPASS Trials And More
December 13, 2022
Psychedelic Therapy Now Available As Workplace Benefit, Free Month For Laid-Off Tech Workers
Via
Benzinga
KCSA Mental Health Virtual Investor Conference Agenda Announced for December 15th
December 13, 2022
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Psychedelic Stock Gainers And Losers From December 12, 2022
December 12, 2022
Via
Benzinga
Major Psychedelic Drug Stocks DOWN 9% Last Week; Now Down 51% YTD
December 11, 2022
Today's article highlights the performance of the largest psychedelic stocks that research the treatment of a variety of mental illnesses based on the use of ten (10) different psychedelic substances.
Via
Talk Markets
Compass Pathways, Mind Medicine Among Top Psychedelic Movers Of Today
December 08, 2022
Via
Benzinga
Numinus Submits Clinical Trial Application to Health Canada for Experiential Psilocybin-Assisted Therapy Training Research
December 08, 2022
New clinical trial will provide experiential training to therapists learning to conduct psilocybin-assisted therapy. Clinical trial dosing will use Numinus Bioscience’s Psilocybin Tea, EnfiniTea – one...
Via
PressReach
Seelos Therapeutics, Numinus Wellness Among Top Psychedelic Movers Of Today
December 06, 2022
Via
Benzinga
Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal's Decrim Project
December 06, 2022
Psychedelic Research & Fed Funding By The National Institute Of Mental Health The National Institute of Mental Health (NIMH) named the types of psychedelics studies to which it would grant funds and...
Via
Benzinga
Seelos Therapeutics, GH Research Among Top Psychedelic Movers Of Today
December 05, 2022
Via
Benzinga
Major Psychedelic Drug Stocks Went Up 7% This Week; Still Down 46% YTD
December 03, 2022
The 6 major psychedelic stocks researching the treatment of a variety of mental illnesses were UP 7% this week and are UP 3 % in the last 6 weeks. The 6 therapy clinic stocks went UP 3% this week and...
Via
Talk Markets
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.